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Summary.-The intracellular adenosine deaminase activities (ADA) in 12 different
experimental animal tumours were measured. Unlike the leukaemic lymphoblasts
of man, those of two spontaneous rat leukaemias did not have elevated levels of the
enzyme. Very high levels were found in a rat plasma-cell tumour (IR 461) and an
attempt was made to treat such tumours with the specific enzyme inhibitor, 2-deoxy-
coformycin. The shortage of this drug prevented a systematic study, but a daily dose
of 8 mg/kg had a significant inhibitory effect on the growth of tumours.
ADENOSE DEAMINASE (EC.3.5.4.4, ADA)
activity has been shown to be widely dis-
tributed in animal tissues (Conway &
Cooke, 1939; Brady & O'Donovan, 1965).
High levels have been found in circulating
lymphocytes (Barnes, 1940), particularly
in those collected during an immune
response, when they include antibody-
forming immunoblasts (Hall, 1963).
Claims that increased amounts of ADA
were detectable in the blood plasma of
most cancer patients (Straub et al., 1957)
were not confirmed by Schwartz &
Bodansky (1959) or by Koehler & Benz
(1962), who found significantly elevated
levels only in patients with infectious
mononucleosis or acute leukaemia. Gen-
eral clinical interest in ADA lapsed, until
the enzyme was found to be reduced or
absent in some cases of combined im-
munodeficiency (Dissing & Knudesn, 1972;
AWebster & Matamoros, 1979) and high
intracellular levels were found in leuk-
aemic lymphoblasts (Smyth & Harrap,
1.975). These findings, together with the
discovery of an efficient, specific and
relatively non-toxic inhibitor, 2-deoxy-
coformycin (Woo et al., 1974), prompted
us to survey the levels of ADA in some
experimental animal tumours.
MATERIALS AND MIETHODS
Anitals.-Rats and mice bearing trans-
plantable, syngeneic tumours wNere taken from
our own barrier-maintained colonies as re-
quired. The particular strains of the animals
and the details of the tumours are specified
in the results section.
Sheep lymph (e.g. Hall et al., 1975) was
used to provide a constant source of fresh
lymphocytes, which were used to provide
positive controls in the assays of intracellular
ADA.
Preparation ofcell extractsfor ADA assay.-
It wA-as easy to obtain fresh suspensions of
normal lymphocytes, lymphomas and leuk-
aemnias, so that the cells could be counted by
standard haematological procedures and
lysed with distilled water to yield an enzyme-
rich supernatant suitable for immediate
assay. However, this method could not be
applied to solid tumours; mechanical dis-
aggregation, even in the presence of col-
lagenase, etc., often gave a poor and unrepre-
sentative yield of cells. Therefore the follow-
ing procedure was adopted throughout. To
each 100 mg (wet wAt) of fresh tumour tissue
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1I0 ml of distilled water was added and the
mixture was teased and divided as finely as
possible with scalpel blades and, where
possible, made into a slurry by forcing it
repeatedly through a hypodermic needle by
means of a syringe. A non-ionic detergent
("Brij 58"; see Hall et al., 1975) was added to
a final concentration of 0.10% and the mix-
ture placed in an ice bath for 30 min and
agitated vigorously every 5 min. The tonicity
and pH of the mixture was then restored to
physiological levels by adding 1/10th vol. of
1-5M phosphate buffer, pH 741; the mixture
was clarified by centrifugation and the super-
natant assayed immediately for ADA.
The malignant blast cells from the blood of
leukaemic rats were separated from the red
cells by centrifugation on "Lymphoprep"
(Nyegaard and Co. A/S, Oslo, Norway). This
reagent absorbs strongly in the UV spectrum
and it was found necessary to wash the
supernatant cells at least twice before pre-
paring extracts for ADA assay.
Protein determination.-The concentration
of protein in the cell extracts was measured
by the method ofHartree (1972) using bovine
serum albumin (Armour Pharmaceutical Co.
Ltd, Eastbourne) as a standard.
Assay of ADA.-The cell extracts were
assayed by measuring spectrophotometrically
the rate of decrease in the absorption at
265 nm of a solution of adenosine (Kalckar,
1947). The particulars of the method have
been described previously (Hall, 1963). One
unit of ADA is defined as the amount needed
to cause a decrease in absorbance units of
0-010 per min under the conditions described.
The activities of the cell extracts were con-
verted to correspond to the number of cells
from which the extracts had been prepared
and/or their protein concentrations. Thus the
activities were finally expressed as units of
ADA per 107 cells or per mg of protein. The
variation between assays on replicate
samples ofthe same extract was under 5%.
Measurement of immunoglobulin A in rat
serum.-The relative amounts of IgA in the
sera from Lou/Wsl rats bearing the IgA-
secreting plasma-cell tumours were measured
by the "rocket" electro-immunochemical
method (Laurell, 1967) in agarose gel con-
taining a rabbit antiserum against rat a
chains (Orlans et at., 1978).
2-Deoxy-coformycin.-This drug was kindly
supplied by Dr J. Smyth of this Institute,
who gave us the small quantities remaining
in the transfusion bottles that had been used
to administer the drug to patients during a
Phase 1 clinical trial. The drug was at a con-
centration of 1 mg/ml in 4.2% (w/v) sodium
bicarbonate, and was diluted further in this
solution before i.p. injection into the test rats.
RESULTS
Stability ofADA
A cell extract was prepared from 1010
fresh sheep lymph cells assayed immedi-
ately for ADA, and divided into 12 por-
tions; 4 were kept at room temperature,
4 at 4°C and 4 at - 20°C. The samples
were then assayed for ADA activity at
daily intervals and the results in Table I
TABLE I.-The rate of decay, according to
temperature, of the activity of adenosine
deaminase extracted from sheep lympho-
cytes. The enzyme activity is expressed as
the percentage of that at zero time
Duration ofstorage time (h)
0 24 48 72 96
Room temp. 100 81 77 47 19
40C 100 73 79 57 24
-200C 100 20 8 16 4
show that the activity declined steadily,
whether the samples were kept at room
temperature or at 4°C, and freezing and
thawing had a variable but always
deleterious effect. For these reasons it
became our standard practice to assay
ADA immediately the extracts were pre-
pared. In these preliminary series ofassays
it was also shown that the presence of the
detergent "Brij 58" did not interfere with
the activity of the enzyme.
ADA in tumour cells
The amount of extractable ADA in
various tumours is shown in Table II. The
enzyme was present in nearly all the
tumours examined but, unlike human
leukaemic lymphoblasts, the rodent leuk-
aemias and lymphomas did not have par-
ticularly high levels. However, high levels
occurred in the rat plasma-cell tumour
that secreted IgA, in all generations ofthe
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TABLE II.-Adenosine deaminase activity in some animal tumours
Mean u ADA
Tumour
None
HRL leukaemia (1)
SAL leukaemia (1)
FeSV sarcoma (2)
FeSV sarcoma
HSN sarcoma (3)
HSN sarcoma
MC3 sarcoma (3)
MC22 sarcoma
WMC sarcoma
FS4 sarcoma
FS6 sarcoma
L5178Y lymphoma (4)
IR33 IgG myeloma (5)
TR461 IgA myeloma (5)
IR461 IgA myeloma
Source
Sheep lymph cells
Hooded rat
August rat
Sheep
In vitro culture
Hooded rat
In vitro culture
Hooded rat
Hooded rat
Wistar rat
DBA2/Cbi mouse
C57BL/Cbi mouse
DBA2/Cbi mouse
LOU/Wsl rat (s.c.)
LOU/Wsl rat (s.c.)
LOU/Wsl rat (ascitic)
No. of
animals
12
3
3
2
1
5
3
3
3
5
3
3
5
3
5
4
per 107 per mg
cells protein
4-1 21*2
1*2 5-7
1-3 5-4
4-5 1-7
9*0 5-3
Not done 15-0
Not done 19-2
Not done 19-7
Not done None detected
Not done 6-6
Not done 4*3
Not done 1*3
12*5 15-2
19-0 20-3
62-0 60-0
63-0 58-8
(1) Wrathmell, 1976; (2) Hall et al., 1975;
1969; (5) Bazin et al., 1972.
tumour examined, irrespective of whether
it had been grown in the peritoneal cavity
or subcutaneously. Because of this it was
selected for treatment with deoxy-cofor-
mycin. Also, because normal IgA levels in
the blood are very low (Orlans et al., 1978)
it was hoped that any effect on tumour
growth would be reflected by changes in
the concentration ofthe paraprotein in the
blood.
Treatment ofIR 461, the rat IgA plasma-cell
tumour, with 2-deoxy-coformycin
In man, a few daily doses of 2-deoxy-
coformycin at 1 mg/kg cause a profound
lymphopenia without other signs of
toxicity (J. Smyth, personal communica-
tion). However, when this dose was given
daily for 5 days to 6 rats with s.c. IgA
plasma-cell tumours, there were no sig-
nificant effects on the growth rate of the
tumours, the levels of lymphocytes and
IgA in the blood, or the general health of
the rats.
In order to determine the dose required
to inhibit intracellular ADA levels, rats
were given various doses and the ADA
content of their tumours measured. The
results in Table III show that only at a
dose of 8 mg/kg did the drug substantially
inhibit the enzyme for 24 h.
(3) Currie & Gage, 1973; (4) Denham et al.,
TABLE III.-Percentage inhibition ofintra-
cellular ADA in s.c. IR 461 plasma-cell
tumours after asingle i.p. dose of2-deoxy-
coformycin
% Inhibition
Dose ,
(mg/kg) at8h at24h
1
4
8
90
98
99
10
15
70
TABLE IV.-The effect of 5 daily i.p. injec-
tions of 2-deoxy-coformycin at 8 mg/kg on
the weights of s.c. IR461 plasma-cell
tumours. The control rats received i.p.
injections of the standard bicarbonate
solution
Tumour wt as % total
body wt
Treated rats 0-1, 0-2, 3-7, 1P7 Mean= 1-4
Control rats 8-3, 7-6, 8-9, 6-9 Mean=7-9
Because ofthe shortage ofthe drug, only
4 tumour-bearing rats could be treated
with daily doses of 8 mg/kg and the results
of doing this for 5 days are shown in
Table IV. In comparison with the control
rats, which had received only bicarbonate
solution, the tumour burden ofthe treated
animals was unquestionably reduced, and
lymphocytes were virtually absent from
their blood. However, although the con-
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trol rats looked healthy in spite of their
tumours, the test rats were relatively
apathetic and immobile.
No obvious reason for this could be
found at postmortem examinations and,
surprisingly, there were no significant
differences between the serum IgA levels
ofthe test and the control animals: in both
groups the levels were grossly elevated.
DISCUSSION
In respect of their content of ADA,
tumours seem to be like normal tissues;
i.e. most cells contain it but in variable
amounts. However, some caution is neces-
sary in assessing the results. The amount
of ADA in a normal lymphocyte is only
impressive when it is remembered that
lymphocytes are small cells when com-
pared, for example, with the very large
cells from an FeSV-induced sarcoma in a
sheep. Similarly, results in terms of
u ADA/mg protein may reflect the ease
with which the contents of a particular
cell may be solubilized, rather than the
absolute amount of enzyme in the cell. In
addition, extraction procedures on frag-
ments ofsolid tumours must yield material
derived in part from any mononuclear cells
thathaveinfiltrated the tumour. However,
such sources oferror cannot easily explain
the very high levels found in the IgA
plasma-cell tumours. Cell suspensions ob-
tained from such tumours were seen by
both light and electron microscopy to be
composed almost entirely of intact malig-
nant plasmablasts, and the association
between high intracellular ADA and non-
malignant immunoblastic proliferation
(Wagner & Ehrich, 1950; Hall, 1963) as
well as the absence of ADA in some
immune-deficient states, lends further
circumstantial support to the validity of
the finding. Nonetheless, it would be
premature to conclude that the retarda-
tion of the growth of the plasma-cell
tumours was a direct result of the inhibi-
tion of their ADA by the 2-deoxy-cofor-
mycin. The effective dose of this drug
made the rats quite ill, and the anti-
tumour effect might have been asecondary
phenomenon. Also, therewasno significant
reduction in the concentration ofmyeloma
protein in the treated rats. This may have
been due to the short duration of the
experiment, or to the possibility that the
mechanism which actively transports IgA
from blood to bile (which in any case in-
volves only polymeric IgA; Orlans et al.,
1978) might have been impaired by the
drug. None ofthese factors can be investi-
gated until inhibitors of ADA are more
freely available, but evidence is accumu-
lating that ADA is critical for the survival,
in vivo, of certain classes of both normal
and malignant lymphoid cells (Hovi et al.,
1976).
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